EICHORCondition: Ischemic Stroke, Acute · Sponsor: Beijing Tiantan Hospital
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Early antiplatelet therapy is promising for further improvement of functional prognosis on the basis of intravenous thrombolytic therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of the early dual antiplatelet therapy (within 6 hours of onset ) of ticagrelor with aspirin combined with intravenous thrombolysis in improving good functional outcome (mRS score 0-1) at 90 days inpatients with ischemic stroke.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Beijing Tiantan Hospital, Capital Medical University | Beijing, Beijing Municipality, China | — |
| The First Hospital of Fangshan District | Beijing, Beijing Municipality, China | — |
| Heyuan City Hospital of Traditional Chinese Medicine | Heyuan, Guangdong, China | — |
| The Fifth Affiliated Hospital, Sun Yat-sen University | Zhuhai, Guangdong, China | — |
| Wuming Hospital of Guangxi Medical University | Nanning, Guangxi, China | — |
| Yulin First People's Hospital | Yulin, Guangxi, China | — |
| Affiliated Hospital of North China University of Science and Technology | Tangshan, Hebei, China | — |
| Linxi County People's Hospital | Xingtai, Hebei, China | — |
| Ningjin County Hospital of Hebei Province | Xingtai, Hebei, China | — |
| Qinghe People's Hospital | Xingtai, Hebei, China | — |
| Renze District People's Hospital | Xingtai, Hebei, China | — |
| Xingtai Ninth Hospital | Xingtai, Hebei, China | — |
+ 48 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06316570